HLUKF News and Press, H Lundbeck A/S From 04/17/19

Minerva Neurosciences ( NERV ) is set to report data from multiple clinical trials in 2019 but roluperidone, which NERV is developing as a treatment for the negative symptoms of schizophrenia, is likely to get a disproportionate amount of attention. NERV and others developing in the negative...

On January 7, 2019, Axsome Therapeutics ( AXSM ) announced results from an 80-patient trial of bupropion vs AXS-05 (bupropion with dextromethorphan) in major depressive disorder ((MDD)). I recently wrote about results from the trial and the five additional upcoming catalysts for AXSM. Compar...

Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder Canada NewsWire MONTREAL, Feb. 22, 2019 MONTREAL , Feb. 22, 2019 /CNW Telbec/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Can...

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2018 Q4 earnings Read more ...

H. Lundbeck A/S ( OTC:HLUKF ): Q4 Non-GAAP EPS of DKK3.75; GAAP EPS of DKK3.29. More news on: H. Lundbeck A/S, H. Lundbeck A/S ADR, Earnings news and commentary, Healthcare stocks news, Read more ...